Brodalumab: Additional Phase III data

Additional data from the double-blind, international Phase III AMAGINE-3 trial in 1,881 patients with moderate to severe plaque psoriasis showed that 59.9% of patients receiving 140 mg subcutaneous brodalumab every 2 weeks and 79.6% of patients receiving 210 mg brodalumab every 2 weeks achieved an sPGA score of “clear” or “almost clear” at week 12, a co-primary endpoint, vs. 57.2% of patients receiving Stelara ustekinumab and 4.1% of patients receiving placebo (p<0.001 for both doses of brodalumab vs. placebo). On a secondary endpoint, 53.4% of patients receiving low-dose brodalumab and 61.2% of patients receiving high-dose brodalumab achieved a Psoriasis Symptom Inventory response at week 12 vs. 51.8% of patients receiving Stelara and 6.3% of patients receiving placebo (p<0.001 for both doses of brodalumab vs. placebo). A responder was defined as a achieving a Psoriasis Symptom Inventory total score of <=8 points with no item scores of >1 point. Data were presented at the American Academy of Dermatology meeting in San Francisco. ...